Value-Based Care in Rheumatology provides a forum for physicians, payers, policymakers, and all those interested in providing optimum value-based, personalized care to patients with rheumatologic conditions. The focus of this publication is to provide coverage of key developments from major rheumatology meetings and the rheumatology literature, complemented by expert commentaries and perspectives from key stakeholders involved in evaluating therapies and treating patients with rheumatic diseases, as well as from those responsible for paying for healthcare.


Value-Based Care in Rheumatology provides physicians with educational materials they can share with their patients so they can better understand risk–benefit and cost discussions about different biologics, the rationale behind certain agent sequencing approaches, the importance of adherence with medication, and the realistic clinical and quality-of-life targets that are attainable. This discussion will facilitate evidence-based, personalized therapy that is also cost-effective.


It is estimated that the number of biologics available for use in RA and other rheumatic diseases will more than double over the next 5 years, and the cost of the biologics will increase. These developments make it imperative that payers have a current perspective on optimal value-based care for patients with rheumatic disease—beyond the drug cost—and Value-Based Care in Rheumatology will seek to provide a forum for that perspective.